BYSI vs. FULC, RVNC, ITOS, ETON, RZLT, CYRX, ERAS, VIGL, CKPT, and TECX
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Fulcrum Therapeutics (FULC), Revance Therapeutics (RVNC), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Rezolute (RZLT), CryoPort (CYRX), Erasca (ERAS), Vigil Neuroscience (VIGL), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry.
BeyondSpring vs. Its Competitors
BeyondSpring (NASDAQ:BYSI) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.
Fulcrum Therapeutics has higher revenue and earnings than BeyondSpring.
Fulcrum Therapeutics has a consensus price target of $6.29, indicating a potential downside of 8.93%. Given Fulcrum Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than BeyondSpring.
In the previous week, BeyondSpring and BeyondSpring both had 2 articles in the media. BeyondSpring's average media sentiment score of 1.32 beat Fulcrum Therapeutics' score of 0.41 indicating that BeyondSpring is being referred to more favorably in the media.
BeyondSpring has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500.
BeyondSpring's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.
40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Fulcrum Therapeutics beats BeyondSpring on 8 of the 13 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
This page (NASDAQ:BYSI) was last updated on 7/2/2025 by MarketBeat.com Staff
Free BYSI Stock Alerts